Local Primary Care

# COSMIC – Local Primary Care GP Federation

**CO**PD **S**pirometry **M**anagement supported by A**I** in a **C**ommunity Setting.

This collaborative working project has been developed in line with Clause 20 of the ABPI Code of Practice.

This summary has been written by Chiesi Limited with consultation and approval from the Collaborative Working Project Team, established with representation from Chiesi Limited and Local Primary Care GP Federation.

This COSMIC collaborative working project is non promotional in nature and does not constitute an endorsement of any product or service. Participation in the project is not linked to the prescribing, recommendation or use of any medicine.

## Aim:

To responsibly embed AI within the NHS using ArtiQ.Spiro to support COPD diagnosis.

ArtiQ.Spiro* will assist interpretation of spirometry results in patients undergoing testing to provide immediate results and re-testing where required to ensure timely COPD diagnosis and reduce NHS spirometry wating lists.

The intended objectives of this collaborative working project are to:

a) Provide NHS partners with access to ArtiQ.Spiro and adequate training and set up support to utilise ArtiQ.Spiro within an NHS setting.
b) Invite 'high risk of having COPD' patients for spirometry, these may be patients who are on waiting lists and/or practice lists for spirometry diagnostic testing.
c) Reduce waiting times for spirometry performance and interpretation within NHS setting.
d) Support 400 people deemed as high risk of having COPD to have spirometry diagnosis.

## Expected benefits for patients, the NHS and Chiesi Ltd

### For Patients:

- Standardisation and consistency in spirometry performance, supported by real time interpretation via ArtiQ.Spiro to enable diagnostic tests to be repeated within one appointment when required.
- Enable consistent and efficient interpretation of spirometry results to support timely identification of COPD and appropriate treatment intervention to reduce the risk of exacerbations.

### For the NHS:

- Support for workforce to promote efficient delivery of spirometry services which will address management of spirometry waiting lists.

- Real time feedback on quality of diagnostic spirometry being performed.
- Enable standardised and consistent spirometry performance and interpretation across services.
- Targeted diagnostics can potentially lead to timely diagnosis and treatment intervention rather than diagnosis occurring in an acute setting at the time of exacerbation.

For Chiesi Limited:

- Improved understanding of barriers and enablers to timely COPD diagnosis and implementation of AI-supported spirometry services within NHS practices.
- Enhanced reputation through support for improvements in NHS services and patient care.
- Increase in COPD population.

## Resource Contribution

This collaborative working project is based on the pooling of resources from Chiesi Limited and the NHS Organisation to support delivery of the agreed shared aims and objectives.

Chiesi Limited will contribute financial support for ArtiQ.Spiro licences/tests and non-promotional staff time to support project meetings, coordination and final reporting.

The NHS partner will contribute staff time to identify eligible patients, support project delivery, participate in agreed meetings, complete the project proforma and review the final report. Together, these contributions enable both organisations to deliver the project in a transparent and proportionate way, with each partner contributing appropriate resources to support timely COPD diagnosis, improved spirometry workflow and the generation of shared learning for future service improvement.

| Contribution Type | Chiesi Limited | NHS | Overall Totals |
|---|---|---|---|
| Financial Contribution | £1650 provided as payment to ArtiQ.Spiro licences/tests & training | £0.00 | £1650 |
| Time Contribution as a financial value | £916.85 | £1668.67 | £2585.52 |
| Total Contribution | £2566.85 | £1668.67 | £4235.52 |
| % of Total Programme Contribution | 61% | 39% | 100% |

## Start Date

The anticipated project period is 12 months starting October 2026; and will automatically expire when all tests are used or after 24 months.

*Neither Chiesi Limited nor ArtiQ.Spiro will influence, direct, or seek to influence clinical decision-making, prescribing behaviour, or treatment choices. ArtiQ.Spiro acts solely as the software technology supplier. All resources, services, and time contributions provided as part of this collaborative working project are proportionate, represent fair market value, and are not intended to induce or reward the use, purchase, or recommendation of any medicine.